By Matt Harrington, BCBA · Behaviorist Book Club · Research-backed answers for behavior analysts
No. Recommending that a client start, stop, or change a medication falls outside the scope of behavior analysis practice and would violate the BACB Ethics Code (2022, Code 1.05). Medication decisions are the domain of prescribing professionals such as physicians, psychiatrists, and nurse practitioners. The BCBA's role is to provide objective behavioral data that informs the medication decision-making process, not to participate in the decision itself. If asked directly by a family for a medication recommendation, the appropriate response is to redirect them to the prescribing professional while offering to share relevant behavioral data.
For stimulant medications, the most relevant behavioral dimensions to track include sustained attention during structured tasks, activity level and motor behavior, impulsivity measures such as response latency and interrupting, mood and emotional regulation, appetite and food consumption during sessions, and any emergence of tics or repetitive behaviors. Track these dimensions at consistent times during ABA sessions and note the time of day relative to medication administration, as stimulant effects vary across the day. Also document the time of medication offset, when effects are expected to wear off, as behavioral changes during this period (sometimes called rebound effects) are clinically significant.
Communication should be objective, data-driven, and free of medication recommendations. Present your observations using behavioral language and, when possible, graphic data displays that show trends before and after medication changes. For example: Since the dosage increase on March 1st, we have observed a 35% decrease in off-task intervals during structured activities, along with a new pattern of session refusal in the final 30 minutes that was not present during baseline. Include relevant context such as session times, other environmental changes, and any caregiver-reported observations. Always obtain family consent before communicating with the prescriber.
Stimulant medications, which include methylphenidate-based and amphetamine-based compounds, typically produce noticeable behavioral effects within 30 to 60 minutes of administration and wear off after several hours depending on the formulation. Their effects on attention, activity level, and impulsivity are generally observable within the first few days of use. Non-stimulant medications, such as atomoxetine, guanfacine, and clonidine, typically take two to six weeks to reach full therapeutic effect. Their behavioral changes may be more gradual and subtle. Non-stimulants may also produce different side effect profiles, including sedation with guanfacine and clonidine. These different timelines have direct implications for how behavior analysts design their data collection plans.
Your role is to present objective behavioral data, not to serve as the caregiver's advocate for a specific medication decision. If the caregiver believes the medication is not effective, acknowledge their concern and offer to share your behavioral data with the prescriber so the prescriber has a complete picture. You might say: I can share our session data with the doctor, which shows what we have been observing behaviorally. That information, combined with what you share about behavior at home, will help the doctor make an informed decision. This approach supports the caregiver's concerns without positioning you as a medication decision-maker.
You should prepare to evaluate whether modifications are needed, but do not make preemptive changes based on assumptions about medication effects. Instead, continue your current programming while adding medication-related data collection to monitor for behavioral changes. If the data show meaningful changes in the client's behavioral profile after the medication change, then adjust your treatment plan accordingly. For example, if a stimulant medication significantly reduces off-task behavior, you might modify your reinforcement schedule to reflect the new baseline. If medication side effects such as decreased appetite reduce the effectiveness of food-based reinforcers, you might expand your reinforcer assessment to identify alternatives.
Document your behavioral observations objectively and communicate them promptly to the prescribing professional and the family. Describe what you are observing in behavioral terms: We have noticed a new pattern of repetitive eye blinking that began approximately three days after the medication change, occurring at a rate of approximately 15 per minute during our last three sessions. This was not observed during the prior six months of service. Do not diagnose the side effect or suggest medication changes. If the behavioral change raises immediate safety concerns, communicate urgency to the family and encourage them to contact the prescriber as soon as possible.
Start by obtaining written consent from the family to communicate with the prescriber. Then introduce yourself through a brief, professional letter or email that explains your role, the nature of your services, and the type of behavioral data you can provide. Many prescribers are not familiar with ABA or the depth of behavioral data that behavior analysts collect. A brief explanation of your observational capacity and your interest in supporting coordinated care is usually well received. Offer to provide data in whatever format is most useful to the prescriber. Establish a mutually agreed-upon communication schedule, such as sending a brief data summary prior to each medication review appointment.
BCBAs should be cautious about providing medication education, as this approaches the scope of prescribing professionals. However, behavior analysts can appropriately share general information about how medication changes might affect behavior during ABA sessions and what behavioral dimensions the team will be tracking. If a family has specific questions about medication mechanisms, dosing, or side effects, redirect them to the prescribing professional. You might say: That is a great question for the doctor. What I can tell you is what we are seeing behaviorally during our sessions, and I can share that data with the doctor to help answer your question.
Medication and behavioral intervention can interact in several ways. Medication that improves attention and reduces hyperactivity may increase a client's availability for learning during ABA sessions, accelerating skill acquisition. Conversely, medication side effects such as fatigue or emotional blunting may reduce responsiveness to reinforcement or decrease engagement. In some cases, behavioral improvements may reduce the perceived need for medication, while in others, medication adjustments may reveal behavioral needs that were previously masked. The behavior analyst's role is to track these interactions through careful data collection and to communicate their observations to the treatment team so that both behavioral and pharmacological interventions can be optimized.
The ABA Clubhouse has 60+ on-demand CEUs including ethics, supervision, and clinical topics like this one. Plus a new live CEU every Wednesday.
Ready to go deeper? This course covers this topic with structured learning objectives and CEU credit.
The ADHD Exchange: A BCBA's Role in Medication Management — Nicole Stewart · 1.5 BACB Ethics CEUs · $22
Take This Course →1.5 BACB Ethics CEUs · $22 · BehaviorLive
Research-backed educational guide with practice recommendations
Side-by-side comparison with clinical decision framework
All behavior-analytic intervention is individualized. The information on this page is for educational purposes and does not constitute clinical advice. Treatment decisions should be informed by the best available published research, individualized assessment, and obtained with the informed consent of the client or their legal guardian. Behavior analysts are responsible for practicing within the boundaries of their competence and adhering to the BACB Ethics Code for Behavior Analysts.